Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, C.-O.
Right arrow Articles by Oyesiku, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, C.-O.
Right arrow Articles by Oyesiku, N. M.
[Cancer Research 63, 4218-4224, July 15, 2003]
© 2003 American Association for Cancer Research


Tumor Biology

Differential Expression of Folate Receptor in Pituitary Adenomas1

Chheng-Orn Evans, Prasad Reddy, Daniel J. Brat, Eric B. O’Neill, Branch Craige, Victoria L. Stevens and Nelson M. Oyesiku2

Department of Neurosurgery and Laboratory of Molecular Neurosurgery and Biotechnology [C-O. E., N. M. O.], Division of Cancer Biology, Departments of Radiation Oncology [E. B. O., B. C., V. L. S.] and Pathology [D. J. B.], Emory University School of Medicine, Atlanta, Georgia 30322, and Vanderbilt University, School of Medicine, Nashville, Tennessee 37232 [P. R.]

Pituitary adenomas cause significant morbidity caused by compression of regional structures or the inappropriate expression of pituitary hormones. However, little is known about the molecular changes that contribute to the development of these tumors. To investigate these changes, we recently used cDNA microarray analysis to identify several genes with altered expression patterns in pituitary adenomas. The folate receptor (FR{alpha}) was significantly overexpressed in clinically nonfunctional (NF) adenomas but not in functional adenomas (adrenocorticorticotropic hormone, growth hormone, and prolactin). FR{alpha} is a high affinity folate transporter that is overexpressed by other tumors and could provide a growth advantage to cells that express it. Analysis of FR{alpha} expression by Western blotting confirmed that FR{alpha} protein was specifically overexpressed in NF tumors. The FR{alpha} was capable of binding folates from measurements of [3H] folic acid binding, indicating that the overexpressed receptor was properly folded and may mediate vitamin uptake. Comparison of protein and specific [3H] folic acid binding levels in subtypes of NF adenomas suggested that the immunohistochemically negative adenomas produced more properly folded FR{alpha} than adenomas that stained positively for anterior pituitary hormones. Finally, immunohistochemistry demonstrated that FR{alpha} was specifically expressed in NF adenoma cells. These results demonstrate that overexpression of FR{alpha} mRNA by NF pituitary adenomas results in production of properly folded FR{alpha} protein, may mediate vitamin transport, and could potentially facilitate the growth of these tumors.




This article has been cited by other articles:


Home page
JNMHome page
R. E. Fisher, B. A. Siegel, S. L. Edell, N. M. Oyesiku, D. E. Morgenstern, R. A. Messmann, and R. J. Amato
Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors
J. Nucl. Med., June 1, 2008; 49(6): 899 - 906.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Shorts-Cary, M. Xu, J. Ertel, B. K. Kleinschmidt-Demasters, K. Lillehei, I. Matsuoka, S. Nielsen-Preiss, and M. E. Wierman
Bone Morphogenetic Protein and Retinoic Acid-Inducible Neural Specific Protein-3 Is Expressed in Gonadotrope Cell Pituitary Adenomas and Induces Proliferation, Migration, and Invasion
Endocrinology, March 1, 2007; 148(3): 967 - 975.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
I. M. Hussaini, C. Trotter, Y. Zhao, R. Abdel-Fattah, S. Amos, A. Xiao, C. U. Agi, G. T. Redpath, Z. Fang, G. K.K. Leung, et al.
Matrix Metalloproteinase-9 Is Differentially Expressed in Nonfunctioning Invasive and Noninvasive Pituitary Adenomas and Increases Invasion in Human Pituitary Adenoma Cell Line
Am. J. Pathol., January 1, 2007; 170(1): 356 - 365.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. S. Moreno, C.-O. Evans, X. Zhan, M. Okor, D. M. Desiderio, and N. M. Oyesiku
Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses
Cancer Res., November 15, 2005; 65(22): 10214 - 10222.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
D. G Morris, M. Musat, S. Czirjak, Z. Hanzely, D. M Lillington, M. Korbonits, and A. B Grossman
Differential gene expression in pituitary adenomas by oligonucleotide array analysis
Eur. J. Endocrinol., July 1, 2005; 153(1): 143 - 151.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.